AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04899674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1358894
Description: BI 1358894
Study NCT05029141 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo regimen
Description: Chidamide 0mg orally twice every week for 2 weeks on days 1, 4, 8, 11, azacytidine 75mg/m2 intravenously daily for 7 days (d3-d9) and HAG regimen (cytarabine, 10 mg/m2 subcutaneously every 12 h on days 3-16; homoharringtonine, 1mg/m2 intravenously every day on days 3-16; and concurrent granulocyte colony-stimulating factor, 200mg/m2/day subcutaneously daily from days 2 to neutral granulocyte recovery. (when WBC > 20×10E9/L, G-CSF paused).~One treatment cycle for 28 days, a total of 2 cycles. If the bone marrow assessment is MLFS on the 28th day in the first cycle, the second cycle of treatment will be started after NE\<1.0×10E9/L; if the delay exceeds 2 weeks, the patient needs to withdraw from the trial.
Study NCT05384119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribociclib
Description: Oral tablet
Study NCT05149989 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Proning Pillow System
Description: Participants will be asked to lie on the proning pillows in prone position for no more than 5 minutes. Each participant will then be asked to lie on standard hospital pillows for no more than 5 minutes.
Study NCT06568874 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) Therapy
Description: Intervention: Patients in this group will receive therapy using VR technology. This involves engaging in various sensorimotor training exercises and tasks in an immersive virtual environment. The VR sessions are designed to be interactive and adaptive, providing real-time feedback to the user. The exercises will target the improvement of motor functions, coordination, and strength of the affected upper extremity.~Duration and Frequency: The specific regimen may involve sessions several times a week, with each session lasting between 30 to 60 minutes, over a period of several weeks or months, depending on the study design.
Study NCT06568874 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Conservative Treatment
Description: Intervention: Patients in this group will receive traditional rehabilitation therapies, which may include:~Physical Therapy (PT): Exercises and activities aimed at improving strength, flexibility, and coordination of the upper limb.~Occupational Therapy (OT): Functional task training to enhance daily living skills and independence, focusing on the use of the upper extremity.~Manual Therapy: Techniques such as massage or joint manipulation to improve mobility and reduce pain.~Home Exercise Programs: Prescribed exercises to be performed at home to reinforce therapy sessions.~Duration and Frequency: Similar to the VR group, this regimen may involve regular sessions several times a week, with each session lasting between 30 to 60 minutes, over a comparable period.
Study NCT06568588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S. boulardii CNCM (National Collection of Cultures of Microorganisms) I-745
Description: 250 mg three times a day for 4 months
Study NCT05691218 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Nebulization
Description: Beta-2 adrenergic agonist administred by standrad nebulization
Study NCT05691218 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A - Vibrating mesh nebulization
Description: Beta-2 adrenergic agonist nebulisation using a vibrating mesh nebuliser device (Aerogen, Galway, Ireland). Nebulisation will take place under medical air at 6L/min or medical O2 at 6L/min depending on the patient's needs and for a SpO2 target between 94-96%
Study NCT05691218 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: B - Vibrating mesh nebulisation and high-flow nasal cannula heated and humidified oxygen
Description: High-flow nasal cannula heated and humidified oxygen (HFNO) and nebulisation of beta-adrenergic agonist using a vibrating mesh device.~HFNO will be administered using an Airvo2 device and beta-2 adrenergic agonist nebulisation enabled by the use of a dedicated heated humidifier and an adaptable vibrating mesh nebuliser device
Study NCT05106179 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atenolol Pill
Description: Atenolol is a second-generation hydrophilic β-1-selective adrenergic antagonist, which is primarily metabolised by the kidneys.
Study NCT05106179 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol Pill
Description: Propranolol is highly lipophilic, nonselective β-blockers, which is primarily metabolised by the liver.
Study NCT05057416 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Adherence
Description: Our current study will compare three exercise groups which will all vary in intensity. Participants will be randomly assigned to one of the three groups. Two groups will be assigned to high intensity bouts of exercise with an active rest between, and one group will perform moderate intensity continuous training without resting. All groups will exercise for 20 minutes. Exercise adherence and it will be measured by a self-report online Google Document.
Study NCT04679233 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prescription aerobic exercise
Description: high intensity interval training, 5 weeks, 2 sessions/week - supervised by a clinician.
Study NCT06288516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benralizumab 30 mg/ml
Description: Benralizumab administered subcutaneously every 4 weeks for the first 3 dose and then every 8 weeks
Study NCT04587934 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iRes Warmer with ResusView
Description: Rapid heart rate display utilizing optimized ECG algorithm in iRes Warmer in babies delivered between 23+0 and 32+6 weeks estimated gestational age
Study NCT04946669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: Abatacept is a CTLA-4 fusion protein that inhibits T cell activation by competitively binding to CD80/CD86 and blocking the second signal. To date, Abatacept has been approved by the FDA for the treatment of three types of rheumatoid immune diseases (refractory rheumatoid arthritis, juvenile idiopathic arthritis, and active psoriatic arthritis). The international consensus of experts recommends abacepil as a second-line regimen for the treatment of refractory dermatomyositis based on the evidence of case reports. However, to date, there is no relevant report or clinical study registration information of Abatacept in the treatment of dermatomyositis.
Study NCT04587934 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: iRes Warmer without ResusView
Description: Electrocardiogram monitoring using external ECG monitor in babies delivered between 23+0 and 32+6 weeks estimated gestational age
Study NCT05166213 — intervention group
Intervention type: OTHER
Intervention: focus group discussions (FGD)
Description: FGD to explore patients' attitudes/ concerns towards OLP implementation into clinical practice by means of assessment of qualitative information: 1) Patients' attitudes towards clinical usage of OLPs 2) Personal acceptance of OLP intervention 3) Perceived ideas, concerns regarding OLP implementation. Core questions: 1) Attitudes: After all that I told you about placebos, i.e. that there is a concept that patients are openly elucidated that they receive placebos: What does this elicit in you/What is your opinion on this? How do you like the idea? 2) Context of Acceptance: Under which conditions would you personally take placebos knowing that they are placebos? 3) Concerns: Why would you not take openly administered placebos? 4) Ideas for clinical implication: How could an open placebo intervention look like in the hospital? Where could it be possible to receive placebos and how could a placebo intervention in the best manner take place? What would be important from your point of view?
Study NCT06366971 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The Patient Education
Description: The patient education will be given through a brochure and the content of the education included an exercise training consisting of simple exercises for lumbar stabilization (supine bridge, cat-camel, and lumbar stretching) and the participants will be asked to perform these exercises in 3 sets of 10 repetitions 3 days a week for 6-weeks.
Study NCT06366971 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Patient Education
Description: The patient education will be given through a brochure and the content of the education included an exercise training consisting of simple exercises for lumbar stabilization (supine bridge, cat-camel, and lumbar stretching) and the participants will be asked to perform these exercises in 3 sets of 10 repetitions 3 days a week for 6-weeks.
Study NCT06366971 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Pelvic Proprioceptive Neuromuscular Facilitation Techniques Training
Description: The content of the pelvic proprioceptive neuromuscular facilitation techniques training will include the application of the anterior depression pattern with the rhythmic initiation technique and the application of the posterior elevation pattern with the contract-relax stretch technique. All PNF techniques will be performed in 3 sets of 10 to 12 repetitions. The pelvic proprioceptive neuromuscular facilitation techniques training will be delivered face to face 3 days a week for 6 weeks by an experienced and trained physiotherapist.
Study NCT05007652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KRN125(pegfilgrastim), PLR001(plerixafor)
Description: 7.2 mg of KRN125 in Day 1 Single subcutaneous administration The concomitant drug PLR001 is administered subcutaneously once daily at a dose of 0.24 mg/kg when meets the criteria. The dosing period is 12-9 hours before apheresis on the following day.
Study NCT05007652 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: KRN8601(filgrastim), PLR001(plerixafor)
Description: 400 ug/m2 of KRN8601 from Day 1 to the end date of the Apheresis Once daily subcutaneous administration The concomitant drug PLR001 is administered subcutaneously once daily at a dose of 0.24 mg/kg when meets the criteria. The dosing period is 12-9 hours before apheresis on the following day.
Study NCT06408116 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: photon
Description: radiation with 4-5 cm safte margin
Study NCT06408116 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: surgical therapy
Description: surgery based on PET-CT/MRI staging
Study NCT06408116 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Chemotherapy
Description: neoadjuvant chemotherapy
Study NCT05459493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TJAOA101
Description: Once enrolled, participants will be administrated TJAOA101
Study NCT05869929 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vegetables
Description: 4-5 servings of vegetables daily, per USDA guidelines.
Study NCT05305599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZED1227
Description: ZED1227 is a peptidomimetic designed to inhibit the activity of human tissue transglutaminase 2 (TG2).
Study NCT05305599 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05118594 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pre-treatment psychotherapy recommendations
Description: After patients complete an intake evaluation and prior to starting therapy, the assigned therapist will receive automatized feedback that consists of recommendations regarding the most suitable interventions (i.e., cognitive, behavioral, interpersonal or patient-centered) for each individual patients, based on patients' baseline characteristics and a machine learning algorithm developed in a previous study. Besides the interventions recommended, therapist will receive within the system guideline and tutorial videos showing how to deliver adequately the specific interventions recommended.
Study NCT06278675 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture needles
Description: 1. Experimental group: Sterile stainless steel needle electroacupuncture treatment was applied, and the acupuncture points were as follows: bilateral Zusanli (ST36), Neiguan (PC6), Hegu (LI4), Shaoshang (LU11), and Feng Long (ST40). 1 time a day, 30 minutes each time, for 7 days.~2. Control group: Placebo needles were applied, and the acupuncture points were as follows: bilateral Zusanli (ST36), Neiguan (PC6), Hegu (LI4), Shaoshang (LU11), and Feng Long (ST40). 1 time a day, 30 minutes each time, for 7 days.
Study NCT06289959 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: cfDNA
Description: After achieving complete metabolic remission (Lugano response assessment criteria) following 6 cycles of R-CHOP-like chemotherapy, patients undergo plasma cfDNA testing upon enrollment，and the follow-up treatment plans are based on cfDNA results.
Study NCT06289959 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: cfDNA
Description: After achieving complete metabolic remission (Lugano response assessment criteria) following 6 cycles of R-CHOP-like chemotherapy, patients undergo plasma cfDNA testing upon enrollment，and the follow-up treatment plans are based on cfDNA results.
Study NCT05928650 — intervention group
Intervention type: OTHER
Intervention: Evaluation of menstrual function
Description: Evaluation of serum estradiol levels and menstrual history characteristics between sprinters, long marathon runners and non-athletes.
Study NCT05274386 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Fabian ventilator with PRICO system (Acutronic Medical Systems AG, Hirzel, Switzerland); SpO2 averaging time set to 4to6 s
Description: The SpO2 averaging time will be set to 4to6 s for the next 12 hours.
Study NCT05274386 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Fabian ventilator with PRICO system (Acutronic Medical Systems AG, Hirzel, Switzerland); SpO2 averaging time set to 10 s
Description: The SpO2 averaging time will be set to 10 s for the next 12 hours.
Study NCT05274386 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Fabian ventilator with PRICO system (Acutronic Medical Systems AG, Hirzel, Switzerland); SpO2 averaging time set to 16 s
Description: The SpO2 averaging time will be set to 16 s for the next 12 hours.
Study NCT05996250 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Immersive virtual reality task
Description: participants will have to wear a virtual reality headset connected to a remote control and will have to perform submersive virtual reality tasks
Study NCT04766749 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RIPC
Description: RIPC is delivered with a standard blood pressure cuff placed on the upper thigh. The cuffs are inflated to 200 mm Hg and keep inflated for 5 minutes,Then deflated to 0 mmHg and keep uninflated for 5 minutes, This cycle is repeated four times
Study NCT03534102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Improved Opioid-Tapering Instructions
Description: Applied to first and second experimental groups in the form of discharge instructions and directions from nursing staff.
Study NCT03534102 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinical Patient Educator
Description: Applied to second experimental group in the form of regular calls about weaning off narcotic medications.
Study NCT05635929 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Composition comprising olive oil, xylitol and betaine
Description: Topical composition in the form of a gel.
Study NCT06515925 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Our Whole Lives (OWL)
Description: OWL is a nine-session, web-accessible, self-paced mindfulness curriculum that has interactive components of self-monitoring and social support (online community). Our Whole Lives (OWL) online curriculum of self-management topics such as mindfulness, mind-body practices, education about chronic pain therapies, stress reduction, sleep, and nutrition.~Once a week for 9 weeks participants will attend a 1.5 -2-hour online group session via Zoom or Google Meets, accessing it through GEMINI platform.
Study NCT06515925 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low Dose Mindfulness Training
Description: The GEMINI platform will facilitate the delivery of a low-dose version of Our Whole Lives program. OWL in this arm is a nine-session, web-accessible, self-paced curriculum, self-monitoring. Participants will interface with the GEMINI platform's static content.
Study NCT06566573 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Pain
Description: The relationship between the degree of stenosis and pain in patients with lumbar spinal stenosis will be evaluated with a visual analogue scale.
Study NCT06566573 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Normal Range of Motion
Description: CROM will be used for normal range of motion (ROM) of the cervical region. Measurements will be made separately for flexion, extension, right rotation, left rotation, right and left lateral flexion.
Study NCT06566573 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Proprioceptive Sense
Description: CROM will be used for cervical proprioception. Measurements will be made separately for flexion, extension, right rotation, left rotation, right and left lateral flexion.
Study NCT06564961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clomiphene Citrate
Description: 50 mg tab once daily
Study NCT06564961 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tab once daily
Study NCT06541561 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcutaneous electrical acupoint stimulation
Description: Patients who meet the enrollment criteria will be randomized 1:1 to either the transcutaneous electrical acupoint stimulation (TEAS) or the sham groups. In the TEAS group, the acupoints are bilateral neiguan (PC6) and Zusanli(ST 36) acupoints.~Patients will receive 30min TEAS before anesthesia until be discharged from the post anaesthesia care unit (PACU). The same treatment for 30 min will be performed on the 1st, 2nd and 3rd days after surgery. The stimulation intensity will be adjusted in accordance with the maximal level tolerated by each patient.
Study NCT06541561 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham transcutaneous electrical acupoint stimulation
Description: Patients in the sham group will receive electrode attachment but without stimulation.
Study NCT05125822 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal replacement and lifestyle modification
Description: Meal replacement and lifestyle modification
Study NCT06561620 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Befotertinib
Description: Befotertinib is a novel, selective oral third-generation epidermal growth factor receptor tyrosine-kinase inhibitor.
Study NCT06023940 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High fiber
Description: A pea fiber supplement is added to a diet of regular foods. Participants receive 25g fiber daily.
Study NCT06344858 — intervention group
Intervention type: DRUG
Intervention: Ketamine
Description: One bolus of ketammine
Study NCT04501159 — intervention group
Intervention type: OTHER
Intervention: blood sample pre, during and post HD
Description: Assessment of ABG pre, during and post HD
Study NCT04501159 — intervention group
Intervention type: DEVICE
Intervention: Non invasive cardiac output assessment
Description: Four ECG style electrodes are placed on the thorax which indirectly measures cardiac output.
Study NCT06249035 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Transoesophageal echocardiography (TEE)
Description: TEE is a diagnostic modality in which an ultrasound probe is inserted via the oesophagus in order to visualize the heart.
Study NCT05692570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBI-200 Tablet
Description: PBI-200 is a TRK inhibitor
Study NCT05692570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir Oral Tablet
Description: Ritonavir is a potent CYP3A inhibitor
Study NCT05692570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobicistat Oral Tablet
Description: Cobicistat is a potent CYP3A inhibitor
Study NCT04054934 — intervention group
Intervention type: BEHAVIORAL
Intervention: Reversed Circadian Rhythm
Description: Revered day/ night sleep cycle
Study NCT04054934 — intervention group
Intervention type: BEHAVIORAL
Intervention: Normal Circadian Rhythm
Description: Normal day/ night sleep cycle
Study NCT06541756 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fibrine Clot-augmented Meniscal Repair
Description: The fibrin clot will be prepared from 50cc of bone marrow aspirate obtained from the iliac crest and mixed for 15 minutes. The fibrin clot will be shaped into a cylindrical form and compressed between the torn edges of the meniscus using a trocar system, then secured with sutures.
Study NCT06541756 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Meniscal Repair
Description: Patients in the standard repair group will undergo routine meniscus repair surgery using arthroscopic all-inside or inside-out sutures.
Study NCT06152653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: n-acetylcystine (NAC)+ albuterol
Description: NAC is a mucolytic drug and Albuterol is a bronchodilator.
Study NCT06152653 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: n-acetylcystine (NAC)+ albuterol
Description: NAC is a mucolytic drug and Albuterol is a bronchodilator.
Study NCT06152653 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AeroEclipse-VersaPAP System
Description: The AeroEclipse-VersaPAP System combine continuous positive inspiratory pressure and nebulizer in one system.